Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Studies Link Legal Marijuana with Fewer Opioid Prescriptions

By MALCOLM RITTER, AP | April 3, 2018

In this Thursday, Feb. 15, 2018 file photo, a woman holds the prescribed medical marijuana product used to treat her daughter’s epilepsy after making a purchase at a medical marijuana dispensary in Butler, Pa. Two new studies released on Monday, April 2, 2018 suggest that legalization of marijuana may reduce the prescribing of opioids. (AP Photo/Keith Srakocic)

Can legalizing marijuana fight the problem of opioid addiction and fatal overdoses? Two new studies in the debate suggest it may.

Pot can relieve chronic pain in adults, so advocates for liberalizing marijuana laws have proposed it as a lower-risk alternative to opioids. But some research suggests marijuana may encourage opioid use, and so might make the epidemic worse.

The new studies don’t directly assess the effect of legalizing marijuana on opioid addiction and overdose deaths. Instead, they find evidence that legalization may reduce the prescribing of opioids. Over-prescribing is considered a key factor in the opioid epidemic.

Both studies were released Monday by the journal JAMA Internal Medicine.

One looked at trends in opioid prescribing under Medicaid, which covers low-income adults, between 2011 and 2016. It compared the states where marijuana laws took effect versus states without such laws. The comparison was done each quarter, so a given state without a law at one point could join the other category once a law kicked in.

Results showed that laws that let people use marijuana to treat specific medical conditions were associated with about a 6 percent lower rate of opioid prescribing for pain. That’s about 39 fewer prescriptions per 1,000 people using Medicaid.

And when states with such a law went on to also allow recreational marijuana use by adults, there was an additional drop averaging about 6 percent. That suggest the medical marijuana laws didn’t reach some people who could benefit from using marijuana instead of opioids, said Hefei Wen of the University of Kentucky in Lexington, one of the study authors.

The other study looked at opioid prescribing nationwide for people using Medicare, which covers people 65 years or older and those with disabilities. Every year from 2010 through 2015, researchers compared states with a medical marijuana law in effect to those without one. Fourteen states plus the District of Columbia had such a law from the beginning of that time; nine other states joined them during the years the study covered.

Researchers found that Medicare patients in states with marijuana dispensaries filled prescriptions for about 14 percent fewer daily doses of opioids than those in other states. Patients in states that only allowed them to grow pot at home showed about 7 percent fewer doses.

W. David Bradford, an economist at the University of Georgia in Athens who’s an author of the second study, said the results add to other findings that suggest to experts that marijuana is a viable alternative to opioids. The weight of that evidence is “now hard to ignore,” said Bradford, who said he thinks federal regulations should be changed to allow doctors to prescribe marijuana for pain treatment.

The two studies have some limitations, Dr. Kevin Hill of Harvard Medical School and Dr. Andrew Saxon of the University of Washington in Seattle wrote in an accompanying editorial.

For one thing, they don’t reveal whether individual patients actually reduced or avoided using opioids because of the increased access to marijuana. The findings in Medicaid and Medicare patients may not apply to other people. And the results may have been skewed by some characteristics of the state populations studied, they wrote.

They called for states and the federal government to pay for more studies to clarify the effect of marijuana use on opioid use, saying such research is needed for science to guide policy-making.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE